Those include an interim analysis of the first 90 patients enrolled, which formed part of the evidence supporting approval of idarucizumab (Praxbind Boehringer Ingelheim ) by the US Food and Drug Administration in October 2015, and a nearly complete analysis of 494 patients reported late last year. The findings, which Pollack presented earlier this week at the International Society on Thrombosis and Haemostasis Congress in Berlin, Germany, and were published simultaneously online in the New England Journal of Medicine, affirm the results of earlier analyses from the study. “Although case reports suggest that thrombolysis and thrombectomy can be performed safely after dabigatran reversal with idarucizumab, postmarketing surveillance would be helpful to monitor the effectiveness of idarucizumab for this and other indications and to further assess its safety.” “Idarucizumab is effective for dabigatran reversal among patients who have uncontrolled bleeding or will be undergoing urgent surgery,” lead author Charles Pollack Jr, MD (Thomas Jefferson University, Philadelphia, PA), and colleagues write. ![]() Idarucizumab, a humanized monoclonal antibody fragment designed to bind strongly to dabigatran, rapidly and safely neutralizes the effects of the anticoagulant, according to final results from the RE-VERSE AD study.
0 Comments
Leave a Reply. |